{"id":"https://genegraph.clinicalgenome.org/r/ff68ad12-2271-457c-8144-edd3bb107680v1.0","type":"EvidenceStrengthAssertion","dc:description":"*OPTN* was first reported in relation to semi-dominant amyotrophic lateral sclerosis (ALS) type 12 in 2010 through homozygosity mapping of 6 Japanese individuals from consanguineous families where two different homozygous null variants and one heterozygous missense variant were discovered (Maruyama et al., PMID: 20428114). ALS is a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord, resulting in fatal paralysis. *OPTN* encodes for optineurin, a multiple domain protein ubiquitously expressed in many tissues, including the brain, skeletal muscle, and the eye. It plays important roles in vesicular trafficking, Golgi maintenance, secretion, receptor recycling, and as an autophagy receptor. It also influences the innate immune response by negatively regulating the NF-κB pathway. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found difference in phenotypic variability and a difference in the types of variants seen in autosomal dominant open angle glaucoma and subtype normal tension glaucoma.  Therefore, the following disease entities have been split into multiple disease entities: ALS 12 (OMIM:613435), primary open angle glaucoma (OMIM: 137760) and susceptibility to normal tension glaucoma (OMIM:606657). 40 variants (missense, nonsense, frameshift, large deletions) that have been reported in 43 probands in 19 publications (PMIDs: 2042814, 26203661, 29558868, 33727253, 34272080, 26740678, 21217154, 21074290, 21220178, 21802176, 21852022, 21613650, 22402017, 23062601, 25382069, 25588603, 26503823, 27534431, 31838784) are included in this curation.  The strongest evidence for optineurin’s role as a causative gene for ALS is recessive loss of function variants, which appear to result in a more severe phenotype; reported monoallelic loss of function and missense variants provide some evidence but may pose more of a risk to develop disease. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. This gene-disease relationship is also supported by experimental evidence including expression studies (PMIDs: 20428114, 21825243), protein interaction (PMID: 23178947), functional alterations in non-patient cells (PMIDs: 25859013, 23178947, 34258561, 23721573, 30519240) animal models (PMIDs: 23178947, 27493188) and rescue experiments in vitro (PMID: 23721573). In summary, *OPTN* is definitively associated with semi-dominant ALS12. This has been repeatedly demonstrated in both research and clinical diagnostic settings and has been upheld overtime. This classification was approved by the ClinGen ALS GCEP on May 10, 2022 (SOP Version 8).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/ff68ad12-2271-457c-8144-edd3bb107680","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2022-05-10T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10096","date":"2022-08-22T11:52:45.511Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/650b8651-2885-4d29-9b79-f778313fe0e6","type":"EvidenceLine","dc:description":"Population of Moroccan Jewish population is so small and the OR score plummets; and questions of the likelihood of relatedness. ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/650b8651-2885-4d29-9b79-f778313fe0e6_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26740678","rdfs:label":"OPTN 691_692insAG Founder Mutation","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/7bd6aff2-080b-4311-871b-ac161b475ad9","type":"Cohort","allGenotypedSequenced":379,"alleleFrequency":0.05277044854881267,"detectionMethod":"FAM-labeled primer pairs were used for fragment analysis on the 3130XL genetics analyzer. Patients carrying the variant were also Sanger confirmed","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/650b8651-2885-4d29-9b79-f778313fe0e6_cc_evidence_item"}],"numWithVariant":20,"relatedCondition":{"id":"obo:MONDO_0013264"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/19a2f01d-e463-41a1-8a42-e8761c251c4d","type":"Cohort","allGenotypedSequenced":1000,"alleleFrequency":0.009,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/650b8651-2885-4d29-9b79-f778313fe0e6_cc_evidence_item"}],"numWithVariant":9},"lowerConfidenceLimit":2,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.00030,"statisticalSignificanceType":"","statisticalSignificanceValue":4.6,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":10.61}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/fe3e601b-6ace-479d-8052-2df9de5c40d5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2bc5259c-81b2-46ce-8c28-4c5bdc0362fc","type":"EvidenceLine","dc:description":"GnomAD (non-neuro)v2.1.1: 0.00001744 (4/229387) East Asian: 0.0002671 (4/14976)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2bc5259c-81b2-46ce-8c28-4c5bdc0362fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31838784","allele":{"id":"https://genegraph.clinicalgenome.org/r/4b9640b6-cf8d-4c46-b0a9-a551c35678fe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1481T>G (p.Leu494Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410975"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/fe3e601b-6ace-479d-8052-2df9de5c40d5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31838784","rdfs:label":"L494W","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":46,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4b9640b6-cf8d-4c46-b0a9-a551c35678fe"},"detectionMethod":"Targeted NGS sequencing of the OPTN gene. 15 FALS cases and 275 SALS cases","firstTestingMethod":"Next generation sequencing panels","previousTesting":true,"previousTestingDescription":"Patients with variants were screened for: C9orf72 expansion, SOD1, FUS, TARDBP, KIF5A, ANXA11, TIA1, CCNF, NEK1, CHCHD10, TUBA4A, TBK1, SQSTM1, MATR3, hnRNPA1, hnRNA2B1, VAPB, VCP, PFN1, SPG11, VCP, ANG, ALS2, DAO, UBQLN2, SIGMAR1, SETX, FIG4, and DCTN1\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2bc5259c-81b2-46ce-8c28-4c5bdc0362fc_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/19c8b588-c964-4e70-9b55-dd4ee5587839_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/54771f27-d629-483e-9647-d02176ccbe44","type":"EvidenceLine","dc:description":"GnomADv2.1.1 (non-neuro)0.00001922 (4/208112)\nE Asian: 0.0002718 (4/13416)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/54771f27-d629-483e-9647-d02176ccbe44_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","allele":{"id":"https://genegraph.clinicalgenome.org/r/12fcdfec-9842-4ad2-8d5b-e71790e80cff","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1546G>C (p.Glu516Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5411012"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/19c8b588-c964-4e70-9b55-dd4ee5587839","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","rdfs:label":"516Q","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":57,"allele":{"id":"https://genegraph.clinicalgenome.org/r/12fcdfec-9842-4ad2-8d5b-e71790e80cff"},"detectionMethod":"Sequenced the whole gene of OPTN","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Pre-screened for C9orf72 expansion, SOD1, TARDBP and FUS\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/54771f27-d629-483e-9647-d02176ccbe44_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ffb3ce2c-848c-4ed1-b6cc-f501dcffda97_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57a2e117-df94-4bfe-919b-42845b87a3c9","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57a2e117-df94-4bfe-919b-42845b87a3c9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A Golgi fragmentation was demonstrated by using immunocytochemistry by using antibodies against GM130. A higher proportion of Golgi apparatus fragmentation was observed in NSC-34 cells with the mutant OPTN vs WT, untreated and control cells. Unfolded protein response  was also investigated using nuclear immunoreactivity response to CHOP. By using an anti-CHOP antibody, followed by quantification, mutant OPTN displayed significant amount CHOP immunoreactivity","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/57a2e117-df94-4bfe-919b-42845b87a3c9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27534431","allele":{"id":"https://genegraph.clinicalgenome.org/r/f12e3f4b-98c8-4e38-9325-bedc4db26afe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.883G>T (p.Val295Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA203267404"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ffb3ce2c-848c-4ed1-b6cc-f501dcffda97","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27534431","rdfs:label":"V295F","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":68,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f12e3f4b-98c8-4e38-9325-bedc4db26afe"},"detectionMethod":"Exome sequencing of 84 ALS patients from 74 families was performed. Variant confirmation was performed via PCR/Sanger sequencing. High throughput genotyping used a custom TaqMan assay","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002380","obo:HP_0030237","obo:HP_0033683","obo:HP_0002015"],"previousTesting":true,"previousTestingDescription":"Analysis of C9orf72 expansion and screened for other \"known ALS genes\"","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/57a2e117-df94-4bfe-919b-42845b87a3c9_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/7a274ca2-2c62-4b3f-b4e3-5f1937fb58cc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/45758184-be24-4252-a9a8-70058166cddb","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/45758184-be24-4252-a9a8-70058166cddb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21802176","allele":{"id":"https://genegraph.clinicalgenome.org/r/3b75a939-afea-4fce-8cd7-5d1803833945","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1360C>G (p.Gln454Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376030035"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/7a274ca2-2c62-4b3f-b4e3-5f1937fb58cc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21802176","rdfs:label":"Q454E","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":67,"allele":{"id":"https://genegraph.clinicalgenome.org/r/3b75a939-afea-4fce-8cd7-5d1803833945"},"firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Patients were screened for SOD1, ANG, FUS, TARDBP, VAPB and VCP\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/45758184-be24-4252-a9a8-70058166cddb_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/3c752a10-4909-4335-a1ec-60f48c29bcf4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4eeebc76-5fff-4552-8d43-d38688a437c5","type":"EvidenceLine","dc:description":"Variant is not well conserved across species, GnomADv2.1.1(non-neuro): 0.00003488 East Asian: 0.0004007","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4eeebc76-5fff-4552-8d43-d38688a437c5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21217154","allele":{"id":"https://genegraph.clinicalgenome.org/r/87ccfe7e-896d-44b1-899e-888044daa8f2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.811C>T (p.Arg271Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410759"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3c752a10-4909-4335-a1ec-60f48c29bcf4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21217154","rdfs:label":"R271C","allele":{"id":"https://genegraph.clinicalgenome.org/r/87ccfe7e-896d-44b1-899e-888044daa8f2"},"detectionMethod":"Sanger sequenced coding regions of x4-16 of OPTN; used 940 ethnically matched controls","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4eeebc76-5fff-4552-8d43-d38688a437c5_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/eba67ad4-ea87-4484-8bff-b9cf4c08a835_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/184b2fdf-5ce3-41aa-ac6f-bafe25e44298","type":"EvidenceLine","dc:description":"GnomADv2.1.1(non-neuro): 0.00002883 (6/208128) European (non-Finnish): 0.00006552 (4/89554)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/184b2fdf-5ce3-41aa-ac6f-bafe25e44298_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21074290","allele":{"id":"https://genegraph.clinicalgenome.org/r/dca6296a-2aee-4405-93d8-2e61d19db6eb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1442C>T (p.Ala481Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410970"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/eba67ad4-ea87-4484-8bff-b9cf4c08a835","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21074290","rdfs:label":"A481V","allele":{"id":"https://genegraph.clinicalgenome.org/r/dca6296a-2aee-4405-93d8-2e61d19db6eb"},"detectionMethod":"Amplified the entire OPTN gene and sequenced with 50bp flank.  190 controls were sequenced for exons 5,12, and 14","firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/184b2fdf-5ce3-41aa-ac6f-bafe25e44298_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4f9f1d4e-84a7-4d12-b7ac-e7d75838182c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0071de34-e250-4f97-b86a-1c8922ba9c7d","type":"EvidenceLine","dc:description":"GnomADv2.1.1 (non-neuro): 0.00008283 (19/229378), European (non-Finnish) 0.0001454 (15/103164)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0071de34-e250-4f97-b86a-1c8922ba9c7d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","allele":{"id":"https://genegraph.clinicalgenome.org/r/4fea20b6-7af7-4ed3-9807-5eff283cb8c8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000010.11:g.13127907A>G (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410944"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4f9f1d4e-84a7-4d12-b7ac-e7d75838182c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","rdfs:label":"1401+4A>G","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4fea20b6-7af7-4ed3-9807-5eff283cb8c8"},"detectionMethod":"Entire coding region of OPTN (exon 4-16) with intron/exon boundaries of 40bp were amplified and directly sequenced by BigDye terminator. Variants were then confirmed in a second round of PCR ","firstTestingMethod":"PCR","phenotypeFreeText":"Lowe limb Onset","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG,TARDBP, FUS","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/0071de34-e250-4f97-b86a-1c8922ba9c7d_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/11326d7d-088f-4ac0-842c-d78b7c91c0ba_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11caaf31-5a63-40db-bdfc-55ae34f2737c","type":"EvidenceLine","dc:description":"Absent from GnomADv2.1.1(non-neuro)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11caaf31-5a63-40db-bdfc-55ae34f2737c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Performed a luciferase assay using NSC-34 cells to assess the ability of various OPTNs to inhibit activation of NF- κB. WT and E50K downregulated NF- κB. Q398X and E478G did not even after stimulation with tumor necrosis factor","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/11caaf31-5a63-40db-bdfc-55ae34f2737c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","allele":{"id":"https://genegraph.clinicalgenome.org/r/856fd4ac-5f7e-4a2f-bf70-f9a25253b123","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1192C>T (p.Gln398Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254103"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/11326d7d-088f-4ac0-842c-d78b7c91c0ba","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Family 2 IV-I","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":52,"allele":{"id":"https://genegraph.clinicalgenome.org/r/856fd4ac-5f7e-4a2f-bf70-f9a25253b123"},"firstTestingMethod":"Homozygosity mapping","phenotypes":"obo:HP_0001260","previousTesting":true,"previousTestingDescription":"Devoid of mutations in SOD1, FUS, TARDBP, VAPB, ANG, CHMP2B, STXN and Dynactin\n","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/11caaf31-5a63-40db-bdfc-55ae34f2737c_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f7c1008f-522b-4af5-8bf2-1bd84405a3df_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00e8cec7-a5b9-412c-b428-b578a728cbd2","type":"EvidenceLine","dc:description":"GnomADv2.1.1(non-neuro): 0.000004805 (1/208,128) European (non Finnish): 0.00001117 (1/89,552), truncates ~72% of protein and eliminates binding sites for many receptors and proteins","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/00e8cec7-a5b9-412c-b428-b578a728cbd2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21802176","allele":{"id":"https://genegraph.clinicalgenome.org/r/35df0a15-a0e1-43a0-a66f-2952efbb40f3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.493C>T (p.Gln165Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376028026"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f7c1008f-522b-4af5-8bf2-1bd84405a3df","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21802176","rdfs:label":"G165X","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":83,"allele":{"id":"https://genegraph.clinicalgenome.org/r/35df0a15-a0e1-43a0-a66f-2952efbb40f3"},"firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Patients were screened for SOD1, ANG, FUS, TARDBP, VAPB and VCP\n","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/00e8cec7-a5b9-412c-b428-b578a728cbd2_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/89bbc0ed-4ba8-422e-916d-269f747cc98e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2981180-d818-4755-8370-0a16ad2bcbee","type":"EvidenceLine","dc:description":"At the time, it is said to be a documented causative variant for POAG. There is a case control publication that shows this variant to be a founder mutation in 2 Jewish populations that will be used to score this variant.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2981180-d818-4755-8370-0a16ad2bcbee_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21220178","allele":{"id":"https://genegraph.clinicalgenome.org/r/7bf62512-58af-4cbf-a4de-4104fb3fd14f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.381_382insAG (p.Asp128fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/647662"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/89bbc0ed-4ba8-422e-916d-269f747cc98e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21220178","rdfs:label":"382_383insAG","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":46,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7bf62512-58af-4cbf-a4de-4104fb3fd14f"},"detectionMethod":"13 coding exons (4-16) and exon -intron boundaries (at least 50bp) were amplified/sequenced. Mutations were confirmed on a second PCR product.","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG, VAPB, TARBP, FUS and DAO","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d2981180-d818-4755-8370-0a16ad2bcbee_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2f8057ff-82fb-438e-8425-ca61d198b784_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35f5e7a9-29eb-43d5-a8b0-d83fd36f0b85","type":"EvidenceLine","dc:description":"Absent form GnomADv2.1.1 (non-neuro)","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/35f5e7a9-29eb-43d5-a8b0-d83fd36f0b85_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Immunohistochemistry was performed. Westerb blot confirmed immunohistochemical observations and qRT-PCR analysis suggests OPTN expression is greatly reduced by mutation. Binding partner TBK1 mRNA seems unaffected","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/35f5e7a9-29eb-43d5-a8b0-d83fd36f0b85_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33727253","allele":{"id":"https://genegraph.clinicalgenome.org/r/22bae7cb-5399-4132-b16b-f4fd3ed70e07","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.649A>T (p.Arg217Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376028381"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/2f8057ff-82fb-438e-8425-ca61d198b784","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33727253","rdfs:label":"R217X","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":49,"allele":{"id":"https://genegraph.clinicalgenome.org/r/22bae7cb-5399-4132-b16b-f4fd3ed70e07"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002380","obo:HP_0012473","obo:HP_0002464","obo:HP_0033683","obo:HP_0002425","obo:HP_0003690"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/35f5e7a9-29eb-43d5-a8b0-d83fd36f0b85_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ea6a6993-534e-4908-8d4c-bb8841942396_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/580eebf6-5629-4749-872d-140b0690ed35","type":"EvidenceLine","dc:description":"Absent in GnomADv2.1.1(non-neuro)","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/580eebf6-5629-4749-872d-140b0690ed35_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","allele":{"id":"https://genegraph.clinicalgenome.org/r/6e79bfb5-774c-420b-9c37-31d4f9949d29","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.67G>T (p.Gly23Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376027070"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ea6a6993-534e-4908-8d4c-bb8841942396","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","rdfs:label":"G23X","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":56,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6e79bfb5-774c-420b-9c37-31d4f9949d29"},"detectionMethod":"Entire coding region of OPTN (exon 4-16) with intron/exon boundaries of 40bp were amplified and directly sequenced by BigDye terminator. Variants were then confirmed in a second round of PCR ","firstTestingMethod":"PCR","phenotypeFreeText":"Lower limb onset","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG,TARDBP, FUS","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/580eebf6-5629-4749-872d-140b0690ed35_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f2e21367-1e07-49dd-aa9b-ee457fac48d4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51479643-3962-45ea-9bdc-a148e321a561","type":"EvidenceLine","dc:description":"This variant has been seen before in previous papers (PMID 21852022 and 21802176) ; downgraded to not overcount this variant. GnomADv2.1.1 (non-neuro) 0.000004805 (1/208,128) European (nF): 0.00001117 (1/89,552)","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51479643-3962-45ea-9bdc-a148e321a561_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26203661","allele":{"id":"https://genegraph.clinicalgenome.org/r/35df0a15-a0e1-43a0-a66f-2952efbb40f3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/8c93ccd8-edaf-4b7b-ad78-75d44ae0a6d5","type":"EvidenceLine","dc:description":"Absent from GnomADv2.1.1(non-neuro)","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8c93ccd8-edaf-4b7b-ad78-75d44ae0a6d5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26203661","allele":{"id":"https://genegraph.clinicalgenome.org/r/43cd6d47-ced6-4bfc-aa5c-f2cf0f9d3dde","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.658del (p.Asp220MetfsTer12)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573051217"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f2e21367-1e07-49dd-aa9b-ee457fac48d4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26203661","rdfs:label":"Sibling 1","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":38,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/43cd6d47-ced6-4bfc-aa5c-f2cf0f9d3dde"},{"id":"https://genegraph.clinicalgenome.org/r/35df0a15-a0e1-43a0-a66f-2952efbb40f3"}],"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Upper arm atrophy","phenotypes":["obo:HP_0002380","obo:HP_0001260","obo:HP_0002445"],"previousTesting":true,"previousTestingDescription":"Devoid of mutations in C9orf72 , SOD1, ANG, FUS, TARDBP, VAPB, SETX, FIG4, SPG11 and ALS2","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/8c93ccd8-edaf-4b7b-ad78-75d44ae0a6d5_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/51479643-3962-45ea-9bdc-a148e321a561_variant_evidence_item"}],"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/5ed82d9f-c716-42c6-9894-85637c23a4b8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3f3cc90-6ada-4023-9bf4-4f55bfd6c8e4","type":"EvidenceLine","dc:description":"GnomAD (non-neuro): 0.0001484 (34/229102) / European (non-Finnish): 0.0002910 (30/103076)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e3f3cc90-6ada-4023-9bf4-4f55bfd6c8e4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","allele":{"id":"https://genegraph.clinicalgenome.org/r/043cb5d0-576c-4c9e-9ccf-147b93106bb7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.941A>T (p.Gln314Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410811"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5ed82d9f-c716-42c6-9894-85637c23a4b8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","rdfs:label":"Q314L","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":24,"allele":{"id":"https://genegraph.clinicalgenome.org/r/043cb5d0-576c-4c9e-9ccf-147b93106bb7"},"detectionMethod":"Entire coding region of OPTN (exon 4-16) with intron/exon boundaries of 40bp were amplified and directly sequenced by BigDye terminator. Variants were then confirmed in a second round of PCR ","firstTestingMethod":"PCR","phenotypeFreeText":"Lower limb Onset","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG,TARDBP, FUS","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/e3f3cc90-6ada-4023-9bf4-4f55bfd6c8e4_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f329d798-8adf-44e2-9b8d-2a019e45a8a9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14e8bc32-41ba-4749-8128-d13b9f3a94e8","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/14e8bc32-41ba-4749-8128-d13b9f3a94e8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25588603","allele":{"id":"https://genegraph.clinicalgenome.org/r/92783432-c8e3-4ac2-a918-5c5da5ad0049","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1340T>G (p.Met447Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA203268586"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/f329d798-8adf-44e2-9b8d-2a019e45a8a9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25588603","rdfs:label":"M447R","allele":{"id":"https://genegraph.clinicalgenome.org/r/92783432-c8e3-4ac2-a918-5c5da5ad0049"},"firstTestingMethod":"Next generation sequencing panels","previousTesting":true,"previousTestingDescription":"Full exon sequencing in BSCL2, CEP112, FUS, MATR3, SOD1, SPG11, TARDBP, UBQLN2, and VCP. Specific area sequencing of ALS2, ANG, CHMP2B, DAO, DCNT1, FIG4, NEFH, PON1, PON2, PON3, PRPH, SETX, SQSTM1, VAPB, and VEGFA","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/14e8bc32-41ba-4749-8128-d13b9f3a94e8_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/a52ad39e-c241-4d7d-891b-26398c4473d3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2acfa50b-2465-4b4d-a34a-7dcc52187f4b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2acfa50b-2465-4b4d-a34a-7dcc52187f4b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Splicing assay reveals the activation of an exonic cryptic donor site at c.442 skipping most of exon 6 and is predicted to abolish the N-terminal leucine zipper domain. This deletion might compromise the interaction with Rab8 and affect OPTN translocation from the Golgi to the nucleus upon apoptotic stimulus.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2acfa50b-2465-4b4d-a34a-7dcc52187f4b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","allele":{"id":"https://genegraph.clinicalgenome.org/r/4ac11840-fd08-4156-8a13-996a1735436b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000010.11:g.13112530_13112640del (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573130144"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a52ad39e-c241-4d7d-891b-26398c4473d3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","rdfs:label":"c.552+1delG","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":49,"allele":{"id":"https://genegraph.clinicalgenome.org/r/4ac11840-fd08-4156-8a13-996a1735436b"},"detectionMethod":"Entire coding region of OPTN (exon 4-16) with intron/exon boundaries of 40bp were amplified and directly sequenced by BigDye terminator. Variants were then confirmed in a second round of PCR ","firstTestingMethod":"PCR","phenotypeFreeText":"Lower limb onset","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG,TARDBP, FUS","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2acfa50b-2465-4b4d-a34a-7dcc52187f4b_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f0317d3e-4191-40b7-885c-b80e8322aba5_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ffbf4e1-a1ad-47d5-b99f-12e51819c07d","type":"EvidenceLine","dc:description":"GnomADv2.1.1(non-neuro): 0.04508 (10334/229218) Euro non Fin: 0.02815 (2902/103,086). Patient was also positive for a path variant in TARDBP. Patient also had increased IOP.  This variant was also found in cis with another OPTN variant.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ffbf4e1-a1ad-47d5-b99f-12e51819c07d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","allele":{"id":"https://genegraph.clinicalgenome.org/r/9c0b93fe-161e-4f36-937d-39ddc32f6c5d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.293T>A (p.Met98Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118632"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/97b8ad58-99df-4d1d-bc20-4165a78943af","type":"EvidenceLine","dc:description":"GnomADv2.1.1(non-neuro) says for \"K332G\"*: 0.9972 (227946/228576) Euro non Fin: 0.9995 (102842/102892). Patient was also positive for a path variant in TARDBP. Patient also had increased IOP.  This variant was also found in cis with another OPTN variant.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97b8ad58-99df-4d1d-bc20-4165a78943af_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","allele":{"id":"https://genegraph.clinicalgenome.org/r/b99d41ed-3781-4658-a6fe-58b3e0d43215","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.964G>A (p.Glu322Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA203267440"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f0317d3e-4191-40b7-885c-b80e8322aba5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","rdfs:label":"M98K and E322K","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":39,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/b99d41ed-3781-4658-a6fe-58b3e0d43215"},{"id":"https://genegraph.clinicalgenome.org/r/9c0b93fe-161e-4f36-937d-39ddc32f6c5d"}],"detectionMethod":"Sequenced OPTN gene with 30bp flank; tested for x5 deletion as well","firstTestingMethod":"PCR","phenotypes":["obo:HP_0002380","obo:HP_0002273"],"previousTesting":true,"previousTestingDescription":"Screened for C9orf72, FUS, TARDBP, SOD1, DCTN1","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/8ffbf4e1-a1ad-47d5-b99f-12e51819c07d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/97b8ad58-99df-4d1d-bc20-4165a78943af_variant_evidence_item"}],"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c13ebf88-8777-4b42-8e43-6f3ad39ef3c3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/896f3cfe-e8ac-462b-8e5e-0ea9dab65684","type":"EvidenceLine","dc:description":"Variant has been scored in another proband in this study","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/896f3cfe-e8ac-462b-8e5e-0ea9dab65684_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Performed a luciferase assay using NSC-34 cells to assess the ability of various OPTNs to inhibit activation of NF- κB. WT and E50K downregulated NF- κB.  Q398X and E478G did not even after stimulation with tumor necrosis factor","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/896f3cfe-e8ac-462b-8e5e-0ea9dab65684_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","allele":{"id":"https://genegraph.clinicalgenome.org/r/f289c023-6bfc-48e2-8762-263dc4efc92c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1433A>G (p.Glu478Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA254105"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c13ebf88-8777-4b42-8e43-6f3ad39ef3c3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Family 4 II-III","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":64,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f289c023-6bfc-48e2-8762-263dc4efc92c"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0007340","obo:HP_0003484","obo:HP_0002015","obo:HP_0001260"],"previousTesting":true,"previousTestingDescription":"Patient was devoid of mutations in SOD1, FUS and TARDBP","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/896f3cfe-e8ac-462b-8e5e-0ea9dab65684_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c8a2d89e-ab21-4abe-9a12-c55eebd493d6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0ca7c728-129b-4953-841b-78cbf4de8231","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0ca7c728-129b-4953-841b-78cbf4de8231_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"TaqMan gene expression assay shows patient had 75-80% reduction in expression and multiplex migration profile was absent compared to control and CSF1R gene","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0ca7c728-129b-4953-841b-78cbf4de8231_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29558868","allele":{"id":"https://genegraph.clinicalgenome.org/r/780fd7bf-eab9-4dbf-9475-d5c5957e4865","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.785C>A (p.Ser262Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410755"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/364ee11e-45fb-4020-8341-a24bbd63f4f1","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/364ee11e-45fb-4020-8341-a24bbd63f4f1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"TaqMan gene expression assay shows patient had 75-80% reduction in expression and multiplex migration profile was absent compared to control and CSF1R gene","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/364ee11e-45fb-4020-8341-a24bbd63f4f1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29558868","allele":{"id":"https://genegraph.clinicalgenome.org/r/1822c9fb-8955-4988-a400-ebd63e1f24a0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1289_1290del (p.Leu430ArgfsTer16)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA592311806"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c8a2d89e-ab21-4abe-9a12-c55eebd493d6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29558868","rdfs:label":"Case Report","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":58,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/1822c9fb-8955-4988-a400-ebd63e1f24a0"},{"id":"https://genegraph.clinicalgenome.org/r/780fd7bf-eab9-4dbf-9475-d5c5957e4865"}],"detectionMethod":"Illumina WGS was performed; variants were Sanger confirmed. Variants in known ALS genes were excluded.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0003484","obo:HP_0030237"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/0ca7c728-129b-4953-841b-78cbf4de8231_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/364ee11e-45fb-4020-8341-a24bbd63f4f1_variant_evidence_item"}],"zygosity":{"id":"cg:BiallelicCompoundHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/329bb7e7-f83b-4576-9d2a-1d8cda0cdb6a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4be99018-5701-4398-87bd-de00cd54a6ed","type":"EvidenceLine","dc:description":"GnomADv2.1.1(non-neuro): 0.002765 (634/229,332) Euro non Fin: 0.0002618 (27/103128). Patient suffered from open angle glaucoma","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4be99018-5701-4398-87bd-de00cd54a6ed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","allele":{"id":"https://genegraph.clinicalgenome.org/r/7b386c27-75a1-4928-9ace-da4a0415894a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1634G>A (p.Arg545Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA118630"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/329bb7e7-f83b-4576-9d2a-1d8cda0cdb6a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","rdfs:label":"R545Q","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":47,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7b386c27-75a1-4928-9ace-da4a0415894a"},"detectionMethod":"Sequenced OPTN gene with 30bp flank; tested for x5 deletion as well","firstTestingMethod":"PCR","phenotypes":["obo:HP_0002015","obo:HP_0001260","obo:HP_0003487"],"previousTesting":true,"previousTestingDescription":"Screened for C9orf72, FUS, TARDBP, SOD1, DCTN1","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/4be99018-5701-4398-87bd-de00cd54a6ed_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5a84dee8-f657-449d-9671-423d14fd4d75_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a31b5c0c-8366-4880-8ca0-ccf7aa57d337","type":"EvidenceLine","dc:description":"GnomADv2.1.1 (non neuro): 0.00002402 (5/208132)\nEast Asian: 0.0003727 (5/13416)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a31b5c0c-8366-4880-8ca0-ccf7aa57d337_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Structure analysis shows this variant is located in the Zinc Finger domain. The delta oxygens on the Asp564 form tightly coupled H-bonds with Thr567. Replacement with a bulky histidine residue would likely introduce stereochemical clashes and affect zinc finger stability","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/a31b5c0c-8366-4880-8ca0-ccf7aa57d337_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31838784","allele":{"id":"https://genegraph.clinicalgenome.org/r/6208737d-fabf-4da9-94f0-bea6acbfff94","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1690G>C (p.Asp564His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5411053"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5a84dee8-f657-449d-9671-423d14fd4d75","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31838784","rdfs:label":"D564H","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6208737d-fabf-4da9-94f0-bea6acbfff94"},"detectionMethod":"Targeted NGS sequencing of the OPTN gene. 15 FALS cases and 275 SALS cases","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0002878","obo:HP_0030902","obo:HP_0001260","obo:HP_0002380","obo:HP_0003484","obo:HP_0007340","obo:HP_0003487"],"previousTesting":true,"previousTestingDescription":"Patients with variants were screened for: C9orf72 expansion, SOD1, FUS, TARDBP, KIF5A, ANXA11, TIA1, CCNF, NEK1, CHCHD10, TUBA4A, TBK1, SQSTM1, MATR3, hnRNPA1, hnRNA2B1, VAPB, VCP, PFN1, SPG11, VCP, ANG, ALS2, DAO, UBQLN2, SIGMAR1, SETX, FIG4, and DCTN1\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a31b5c0c-8366-4880-8ca0-ccf7aa57d337_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/bbe29caa-8e72-4f3c-8bec-cd9c121257b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17263514-db9d-4e98-bb84-ef3749870dde","type":"EvidenceLine","dc:description":"GnomAD (non-neuro): 0.000009614 (2/208024)\nEuropean (non Finish): 0.00001117 (1/89506)\nLatino: 0.00003277 (1/30516)\nAbsent in 509 controls","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17263514-db9d-4e98-bb84-ef3749870dde_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21220178","allele":{"id":"https://genegraph.clinicalgenome.org/r/b6760b2d-8daf-4bd9-98bc-21c2829e4006","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.287G>T (p.Arg96Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410556"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/bbe29caa-8e72-4f3c-8bec-cd9c121257b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21220178","rdfs:label":"R96L","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":56,"allele":{"id":"https://genegraph.clinicalgenome.org/r/b6760b2d-8daf-4bd9-98bc-21c2829e4006"},"detectionMethod":"13 coding exons (4-16) and exon -intron boundaries (at least 50bp) were amplified/sequenced. Mutations were confirmed on a second PCR product.","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG, VAPB, TARBP, FUS and DAO","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/17263514-db9d-4e98-bb84-ef3749870dde_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c1b845b1-fc10-41f4-8b97-6d0aaad4e13a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7a121c2-62c9-4e57-8eab-5aed4502f322","type":"EvidenceLine","dc:description":"GnomADv2.1.1 (non-neuro): 0.00006247\nE Asian: 0.0007454 (10/13416)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7a121c2-62c9-4e57-8eab-5aed4502f322_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","allele":{"id":"https://genegraph.clinicalgenome.org/r/16fbf951-e4d3-43c5-b26e-84b9d6c9a734","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.407C>T (p.Ala136Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410619"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c1b845b1-fc10-41f4-8b97-6d0aaad4e13a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","rdfs:label":"A136V","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":46,"allele":{"id":"https://genegraph.clinicalgenome.org/r/16fbf951-e4d3-43c5-b26e-84b9d6c9a734"},"detectionMethod":"Sequenced the whole gene of OPTN","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Pre-screened for C9orf72 expansion, SOD1, TARDBP and FUS\n","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d7a121c2-62c9-4e57-8eab-5aed4502f322_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/682e32eb-bcba-49de-a188-24e2fcc38e98_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2be8ef97-1a8c-4d1e-9e8a-e80ed8f9f129","type":"EvidenceLine","dc:description":"Absent from GnomADv2.1.1(non-neuro)","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2be8ef97-1a8c-4d1e-9e8a-e80ed8f9f129_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21074290","allele":{"id":"https://genegraph.clinicalgenome.org/r/18cdd2cd-3182-4ff8-a56b-552b94c63430","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1242+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376029767"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/682e32eb-bcba-49de-a188-24e2fcc38e98","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21074290","rdfs:label":"c.1242+1G>AinsA","allele":{"id":"https://genegraph.clinicalgenome.org/r/18cdd2cd-3182-4ff8-a56b-552b94c63430"},"detectionMethod":"Sequenced the OPTN gene","firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/2be8ef97-1a8c-4d1e-9e8a-e80ed8f9f129_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/12df8f13-0a88-4e49-beb9-863165930892_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8247982b-8d6c-446a-8dce-3337ba16828a","type":"EvidenceLine","dc:description":"GnomADv2.1.1(non-neuro): 0.000008720 (2/229,370) Euro non Fin: 0.00001939 (2/103158)","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8247982b-8d6c-446a-8dce-3337ba16828a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","allele":{"id":"https://genegraph.clinicalgenome.org/r/8b628cef-bd7d-45a5-84b3-f69acdb92ca9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1320del (p.Lys440fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA592311808"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/12df8f13-0a88-4e49-beb9-863165930892","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23062601","rdfs:label":"K440Nfs*8","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":63,"allele":{"id":"https://genegraph.clinicalgenome.org/r/8b628cef-bd7d-45a5-84b3-f69acdb92ca9"},"detectionMethod":"Sequenced OPTN gene with 30bp flank; tested for x5 deletion as well","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Screened for C9orf72, FUS, TARDBP, SOD1, DCTN1","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8247982b-8d6c-446a-8dce-3337ba16828a_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/32f062f7-7213-4512-8f8e-b62ff6f5d29d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a96d4e8-7fbb-4785-8afb-311b6dde8503","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9a96d4e8-7fbb-4785-8afb-311b6dde8503_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25588603","allele":{"id":"https://genegraph.clinicalgenome.org/r/57bed0bf-32ed-4be2-9e90-41a9b5a1befe","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000010.11:g.13127905T>G (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376030136"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/32f062f7-7213-4512-8f8e-b62ff6f5d29d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25588603","rdfs:label":"c.1401+2T>G","allele":{"id":"https://genegraph.clinicalgenome.org/r/57bed0bf-32ed-4be2-9e90-41a9b5a1befe"},"previousTesting":true,"previousTestingDescription":"Full exon sequencing in BSCL2, CEP112, FUS, MATR3, SOD1, SPG11, TARDBP, UBQLN2, and VCP. Specific area sequencing of ALS2, ANG, CHMP2B, DAO, DCNT1, FIG4, NEFH, PON1, PON2, PON3, PRPH, SETX, SQSTM1, VAPB, and VEGFA","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/9a96d4e8-7fbb-4785-8afb-311b6dde8503_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ebdc3955-ca07-48fb-b4eb-fd6406de363b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a118dfbf-2728-4645-b123-6a0ee37b11f2","type":"EvidenceLine","dc:description":"Scored sibling with same mutation","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a118dfbf-2728-4645-b123-6a0ee37b11f2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","allele":{"id":"https://genegraph.clinicalgenome.org/r/cf589c3d-00a7-49f9-a1f0-10f72a6d5b9e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"OPTN, EX5DEL","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/7100"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ebdc3955-ca07-48fb-b4eb-fd6406de363b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Family 1 V-2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":36,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cf589c3d-00a7-49f9-a1f0-10f72a6d5b9e"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0003484","obo:HP_0001260","obo:HP_0002015","obo:HP_0001308","obo:HP_0004887"],"previousTesting":true,"previousTestingDescription":"Devoid of mutations in SOD1, FUS, and TARDBP","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a118dfbf-2728-4645-b123-6a0ee37b11f2_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d1e04adf-2181-4c9d-8719-e5a263480ab4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b20e452-53aa-445a-9729-d4439edf63c5","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b20e452-53aa-445a-9729-d4439edf63c5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22402017","allele":{"id":"https://genegraph.clinicalgenome.org/r/ae695db7-e2fe-4082-96d4-6087a1c7c017","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000010.11:g.(?_13109113)_(13112645_?)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/832940"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d1e04adf-2181-4c9d-8719-e5a263480ab4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22402017","rdfs:label":"x3-5 deletion","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":44,"allele":{"id":"https://genegraph.clinicalgenome.org/r/ae695db7-e2fe-4082-96d4-6087a1c7c017"},"detectionMethod":"qPCR was performed using 15 TaqMan probes covering all 16 exons of OPTN","firstTestingMethod":"Other","previousTesting":true,"previousTestingDescription":"OPTN gene sequencing","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0b20e452-53aa-445a-9729-d4439edf63c5_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/74e99957-01c6-4d1a-9b01-ae9b102de83e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d36aeb7b-604e-4c9b-900c-0a46c9378019","type":"EvidenceLine","dc:description":"GnomADv2.1.1 (non-neuro): 0.000009610 (2/208122)\n","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d36aeb7b-604e-4c9b-900c-0a46c9378019_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","allele":{"id":"https://genegraph.clinicalgenome.org/r/aba10f46-d8da-4d26-b530-cbcd32ec9a6b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1352T>C (p.Ile451Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410939"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/74e99957-01c6-4d1a-9b01-ae9b102de83e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","rdfs:label":"I451T","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":23,"allele":{"id":"https://genegraph.clinicalgenome.org/r/aba10f46-d8da-4d26-b530-cbcd32ec9a6b"},"detectionMethod":"Sequenced the whole gene of OPTN","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Pre-screened for C9orf72 expansion, SOD1, TARDBP and FUS\n","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/d36aeb7b-604e-4c9b-900c-0a46c9378019_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/acd5f9c9-ab93-4df0-b1ca-82506dfda299_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa0a1e83-fe91-4fe6-a7e9-c992e93d7d8b","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa0a1e83-fe91-4fe6-a7e9-c992e93d7d8b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25382069","allele":{"id":"https://genegraph.clinicalgenome.org/r/36cc28a8-f338-44a1-8f14-0227b29fa3b5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.703C>T (p.Gln235Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376028502"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/acd5f9c9-ab93-4df0-b1ca-82506dfda299","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25382069","rdfs:label":"Q235X","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":72,"allele":{"id":"https://genegraph.clinicalgenome.org/r/36cc28a8-f338-44a1-8f14-0227b29fa3b5"},"firstTestingMethod":"Next generation sequencing panels","previousTesting":true,"previousTestingDescription":"Proband did not have mutations in C9orf72, ATXN2, SOD1, FUS, TARDBP, ANG, OPTN, VCP, VAPB, DAO, DCTN1, FIG4, SETX, TAF15, EWSR1, UBQLN2, and SQSTM1","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/fa0a1e83-fe91-4fe6-a7e9-c992e93d7d8b_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1cc9d572-ffbc-424a-acf4-a5e53eed8e4b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/83cad8d7-48db-43fc-9cfd-a22e9630ff79","type":"EvidenceLine","dc:description":"While absent in GnomAD, this variant was also found in a healthy control.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/83cad8d7-48db-43fc-9cfd-a22e9630ff79_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","allele":{"id":"https://genegraph.clinicalgenome.org/r/745a361c-fd66-4fa5-b076-8ad0c33ffcdf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1184A>G (p.Lys395Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376029633"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1cc9d572-ffbc-424a-acf4-a5e53eed8e4b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26503823","rdfs:label":"K395R","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":32,"allele":{"id":"https://genegraph.clinicalgenome.org/r/745a361c-fd66-4fa5-b076-8ad0c33ffcdf"},"detectionMethod":"Sequenced the whole gene of OPTN","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Pre-screened for C9orf72 expansion, SOD1, TARDBP and FUS\n","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/83cad8d7-48db-43fc-9cfd-a22e9630ff79_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1e93290c-6ed6-4d7f-b4dd-23bcfcf6fc42_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c43272ff-7a06-4866-ab47-75f0415e9ea9","type":"EvidenceLine","dc:description":"Variant has been seen in a previous paper (PMID: 21802176). Reduced to half per protocol.  Variant seen in father, who also experienced symptoms.  RFLP analysis performed; PCR of exon 6 and digested with PstI and ran on agarose. Normal allele resulted in two fragments (232bp and 187bp) while the mutant allele was 419bp ","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c43272ff-7a06-4866-ab47-75f0415e9ea9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21852022","allele":{"id":"https://genegraph.clinicalgenome.org/r/35df0a15-a0e1-43a0-a66f-2952efbb40f3"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1e93290c-6ed6-4d7f-b4dd-23bcfcf6fc42","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21852022","rdfs:label":"Q165X (proband IV)","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":42,"allele":{"id":"https://genegraph.clinicalgenome.org/r/35df0a15-a0e1-43a0-a66f-2952efbb40f3"},"detectionMethod":"Whole gene sequencing of OPTN","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Devoid of mutations in SOD1, FUS, and TARDBP","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/c43272ff-7a06-4866-ab47-75f0415e9ea9_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f469a70a-17a9-4cbb-be3e-6eb0b3768cfc_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ccbdbf0c-4f46-4dfc-98ab-12cd715f2d13","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ccbdbf0c-4f46-4dfc-98ab-12cd715f2d13_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"qPCR reveals significant decrease in expression in OPTN; treated fibroblasts with heterozygous and homozygous mutant alleles with CHX to test if mutant allele goes through NMD. Also did mitochondrial characterization","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ccbdbf0c-4f46-4dfc-98ab-12cd715f2d13_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34272080","allele":{"id":"https://genegraph.clinicalgenome.org/r/988979d2-8044-4a8c-83ee-57b785de0db9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.521C>A (p.Ser174Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376028084"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f469a70a-17a9-4cbb-be3e-6eb0b3768cfc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34272080","rdfs:label":"S174X","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":54,"allele":{"id":"https://genegraph.clinicalgenome.org/r/988979d2-8044-4a8c-83ee-57b785de0db9"},"firstTestingMethod":"Exome sequencing","previousTesting":true,"previousTestingDescription":"Devoid of dementia and known ALS genes as well as C9orf72 expansion","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ccbdbf0c-4f46-4dfc-98ab-12cd715f2d13_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/c20f3bd6-1d31-4c25-ba62-d675f4c76fc8_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb6d809d-d874-476e-811c-e276c09b051e","type":"EvidenceLine","dc:description":"GnomAD( non-neuro): 0.00003923 (9/229390) S.Asian: 0.0002287 (7/30608) European (non-Finnish): 0.000009693 (1/103170)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fb6d809d-d874-476e-811c-e276c09b051e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","allele":{"id":"https://genegraph.clinicalgenome.org/r/aeedc9dd-af7f-47f9-b9bf-840bbb0be704","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.844A>C (p.Thr282Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410763"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/c20f3bd6-1d31-4c25-ba62-d675f4c76fc8","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","rdfs:label":"T282P","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":71,"allele":{"id":"https://genegraph.clinicalgenome.org/r/aeedc9dd-af7f-47f9-b9bf-840bbb0be704"},"detectionMethod":"Entire coding region of OPTN (exon 4-16) with intron/exon boundaries of 40bp were amplified and directly sequenced by BigDye terminator. Variants were then confirmed in a second round of PCR ","firstTestingMethod":"PCR","phenotypeFreeText":"Lower limb onset","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG,TARDBP, FUS","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/fb6d809d-d874-476e-811c-e276c09b051e_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b0128380-a45a-466f-8371-429f60700116_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/780b12c9-97b3-4198-b379-6be96cdeaa22","type":"EvidenceLine","dc:description":"Variant scored already in same study","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/780b12c9-97b3-4198-b379-6be96cdeaa22_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Performed a luciferase assay using NSC-34 cells to assess the ability of various OPTNs to inhibit activation of NF- κB. WT and E50K downregulated NF- κB. Q398X and E478G did not even after stimulation with tumor necrosis factor","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/780b12c9-97b3-4198-b379-6be96cdeaa22_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","allele":{"id":"https://genegraph.clinicalgenome.org/r/856fd4ac-5f7e-4a2f-bf70-f9a25253b123"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b0128380-a45a-466f-8371-429f60700116","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Family 3 II-I","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":44,"allele":{"id":"https://genegraph.clinicalgenome.org/r/856fd4ac-5f7e-4a2f-bf70-f9a25253b123"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0001308","obo:HP_0003690","obo:HP_0007289"],"previousTesting":true,"previousTestingDescription":"Patient was devoid of mutations in SOD1, FUS and TARDBP","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/780b12c9-97b3-4198-b379-6be96cdeaa22_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/aaa010ce-ec44-4725-b993-0a6f958429b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc4ad445-7684-4279-9488-3f09631c9056","type":"EvidenceLine","dc:description":"GnomAD (non neuro)v2.1.1: 0.00001922 (4/208112)\nEast Asian: 0.0002982 (4/13416)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc4ad445-7684-4279-9488-3f09631c9056_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31838784","allele":{"id":"https://genegraph.clinicalgenome.org/r/12fcdfec-9842-4ad2-8d5b-e71790e80cff"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/aaa010ce-ec44-4725-b993-0a6f958429b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31838784","rdfs:label":"E516Q","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":38,"allele":{"id":"https://genegraph.clinicalgenome.org/r/12fcdfec-9842-4ad2-8d5b-e71790e80cff"},"detectionMethod":"Targeted NGS sequencing of the OPTN gene. 15 FALS cases and 275 SALS cases","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0003484","obo:HP_0002015","obo:HP_0002380","obo:HP_0003487","obo:HP_0001260","obo:HP_0030902"],"previousTesting":true,"previousTestingDescription":"Patients with variants were screened for: C9orf72 expansion, SOD1, FUS, TARDBP, KIF5A, ANXA11, TIA1, CCNF, NEK1, CHCHD10, TUBA4A, TBK1, SQSTM1, MATR3, hnRNPA1, hnRNA2B1, VAPB, VCP, PFN1, SPG11, VCP, ANG, ALS2, DAO, UBQLN2, SIGMAR1, SETX, FIG4, and DCTN1\n","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/fc4ad445-7684-4279-9488-3f09631c9056_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ecb0c27f-4d4e-4279-a821-500d10ddb67f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3183e31d-fc37-49fa-bff8-3507f964dca3","type":"EvidenceLine","dc:description":"Variant was also seen in a control in her 80's at the time of collection without motor neuron disease symptoms.  GnomADv2.1.1 (non-neuro): 0.00001444","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3183e31d-fc37-49fa-bff8-3507f964dca3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21074290","allele":{"id":"https://genegraph.clinicalgenome.org/r/e542ddc0-0bc7-43bd-bbe0-391603cc6f19","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.177G>C (p.Lys59Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376027318"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ecb0c27f-4d4e-4279-a821-500d10ddb67f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21074290","rdfs:label":"K59N","allele":{"id":"https://genegraph.clinicalgenome.org/r/e542ddc0-0bc7-43bd-bbe0-391603cc6f19"},"firstTestingMethod":"PCR","previousTesting":false,"sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3183e31d-fc37-49fa-bff8-3507f964dca3_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0886b9f6-ad42-4bcb-b2d2-16ab618b37ce_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd42c0b1-8313-4e0a-9bc1-29fbc317d10e","type":"EvidenceLine","dc:description":"This variant in heterozygous zygosity has been seen in many different functional papers by different authors that this variant acts like the truncating variants. Absent from Gnomadv2.1.1 (non-neuro)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd42c0b1-8313-4e0a-9bc1-29fbc317d10e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Performed a luciferase assay using NSC-34 cells to assess the ability of various OPTNs to inhibit activation of NF- κB. \nWT and E50K downregulated NF- κB\nQ398X and E478G did not even after stimulation with tumor necrosis factor\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/cd42c0b1-8313-4e0a-9bc1-29fbc317d10e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","allele":{"id":"https://genegraph.clinicalgenome.org/r/f289c023-6bfc-48e2-8762-263dc4efc92c"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0886b9f6-ad42-4bcb-b2d2-16ab618b37ce","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Family 4 II-II","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":56,"allele":{"id":"https://genegraph.clinicalgenome.org/r/f289c023-6bfc-48e2-8762-263dc4efc92c"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0002015","obo:HP_0003484","obo:HP_0002878","obo:HP_0001260"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/cd42c0b1-8313-4e0a-9bc1-29fbc317d10e_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c40bfb45-bdd2-46ec-937d-2be0fd1c2e04_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d09951c9-9495-43e8-a0ad-ecbe4dc09087","type":"EvidenceLine","dc:description":"Absent in GnomADv2.1.1(non-neuro)","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d09951c9-9495-43e8-a0ad-ecbe4dc09087_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21217154","allele":{"id":"https://genegraph.clinicalgenome.org/r/b23fa3ed-e96f-4432-a9d9-094f7c0e2903","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.277G>C (p.Ala93Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376027554"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/c40bfb45-bdd2-46ec-937d-2be0fd1c2e04","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21217154","rdfs:label":"A93P","allele":{"id":"https://genegraph.clinicalgenome.org/r/b23fa3ed-e96f-4432-a9d9-094f7c0e2903"},"detectionMethod":"Screened 713 Japanese ALS patients for OPTN mutations in exons 4-16, used 940 ethnically matched controls.  Used rt qPCR to check for deletion","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/d09951c9-9495-43e8-a0ad-ecbe4dc09087_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/9334abdc-bd97-45ac-b22b-dbbadc98bc75_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4534726c-1e43-4bc3-85cd-621a5f9c62a2","type":"EvidenceLine","dc:description":"Absent from GnomAD. Variant is located in zinc finger domain","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4534726c-1e43-4bc3-85cd-621a5f9c62a2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","allele":{"id":"https://genegraph.clinicalgenome.org/r/e1633395-73c8-4d2e-8cb5-91e111cb683e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.1670A>C (p.Lys557Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA376030760"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/9334abdc-bd97-45ac-b22b-dbbadc98bc75","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21613650","rdfs:label":"K557T","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":47,"allele":{"id":"https://genegraph.clinicalgenome.org/r/e1633395-73c8-4d2e-8cb5-91e111cb683e"},"detectionMethod":"Entire coding region of OPTN (exon 4-16) with intron/exon boundaries of 40bp were amplified and directly sequenced by BigDye terminator. Variants were then confirmed in a second round of PCR ","firstTestingMethod":"PCR","phenotypeFreeText":"Lower limb onset","previousTesting":true,"previousTestingDescription":"Patients were devoid of mutations in SOD1, ANG,TARDBP, FUS","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4534726c-1e43-4bc3-85cd-621a5f9c62a2_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/fbb50dfb-ee70-4b63-af97-4b9604727baa_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e8fa4f6-6ef4-4951-8602-3f040e4f6cd8","type":"EvidenceLine","dc:description":"GnomAD (non-neuro): 0.000009609 (2/208136)\nEuorpean (non Finnish): 0.00002233 (2/89558)\nFound in control (age 62) and had no neurological complaints","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e8fa4f6-6ef4-4951-8602-3f040e4f6cd8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21802176","allele":{"id":"https://genegraph.clinicalgenome.org/r/69671521-ca64-47d1-a948-7108817c716f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001008212.2(OPTN):c.476G>T (p.Gly159Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5410632"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/fbb50dfb-ee70-4b63-af97-4b9604727baa","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21802176","rdfs:label":"G159V","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":58,"allele":{"id":"https://genegraph.clinicalgenome.org/r/69671521-ca64-47d1-a948-7108817c716f"},"firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"Patients were screened for SOD1, ANG, FUS, TARDBP, VAPB and VCP\n","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e8fa4f6-6ef4-4951-8602-3f040e4f6cd8_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/06b0da2b-7803-4bce-8415-dc07b04c6712_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/64b59f75-db45-49b5-93f9-b20d518ce541","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/64b59f75-db45-49b5-93f9-b20d518ce541_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","allele":{"id":"https://genegraph.clinicalgenome.org/r/cf589c3d-00a7-49f9-a1f0-10f72a6d5b9e"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/06b0da2b-7803-4bce-8415-dc07b04c6712","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Family 1 V-I","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":33,"allele":{"id":"https://genegraph.clinicalgenome.org/r/cf589c3d-00a7-49f9-a1f0-10f72a6d5b9e"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0003484","obo:HP_0004887","obo:HP_0002015"],"previousTesting":true,"previousTestingDescription":"Patient was devoid of variants in SOD1, FUS, and TARDBP","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/64b59f75-db45-49b5-93f9-b20d518ce541_variant_evidence_item"},"zygosity":{"id":"cg:BiallelicHomozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/cb2cbf38-56e8-46b4-a991-636fd7f85ef1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5623a2ed-9ff0-4fae-8b8f-ab9265a46eb1","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5623a2ed-9ff0-4fae-8b8f-ab9265a46eb1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22402017","allele":{"id":"https://genegraph.clinicalgenome.org/r/eaba8cda-5a6d-40f1-8b2b-f2d5096c1204","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000010.11:g.(?_13116257)_(13116350_?)del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/831344"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/cb2cbf38-56e8-46b4-a991-636fd7f85ef1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22402017","rdfs:label":"exon 1-4 deletion","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":43,"allele":{"id":"https://genegraph.clinicalgenome.org/r/eaba8cda-5a6d-40f1-8b2b-f2d5096c1204"},"detectionMethod":"15 TaqMan probes across the OPTN gene for qPCR","firstTestingMethod":"Other","previousTesting":true,"previousTestingDescription":"Screened for OPTN mutations","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5623a2ed-9ff0-4fae-8b8f-ab9265a46eb1_variant_evidence_item"},"zygosity":{"id":"cg:MonoallelicHeterozygous"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a27b23a5-502c-4de7-9317-45b65f86dbfb","type":"EvidenceLine","dc:description":"Zebrafish is not a strong model to demonstrate human disease compared to more ideal models such as mice. To keep consistency with a prior gene curation of CCNF, I downgraded this model ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9daaaa5b-af27-46bb-aaa0-8a0cd6e38685","type":"Finding","dc:description":"ALS is characterized by affecting the motor neurons.  This model demonstrates knockout of OPTN affects the motor neurons by problems with development - the axons are shorter and have abnormal branching. The same can be seen when the authors used a SOD1 model along side the OPTN depletion","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23178947","rdfs:label":"Zebrafish motor axonopathy","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/37d7a5ab-3bb6-4abd-85b9-91f7ee2d18b1","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9bbec16b-18f3-42bf-ad7d-a7e65ebf8054","type":"Finding","dc:description":"Motor axons die by Wallerian degeneration in ALS. Mouse OPTN-K/O axons were reduced in number and had abnormal myelination along with other axonal pathologies.  Motor function deficiency was also noted","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27493188","rdfs:label":"OPTN-KO mouse RIPK1 effects","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/e086692f-6e53-41ef-8b34-9e86e6a83755","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc9b47e7-6b3f-49c5-8d12-a8508e64c8c4","type":"Finding","dc:description":"ALS mutants failed to rescue the percentage of dead cells compared to WT and glaucoma mutants","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23721573","rdfs:label":"Trypan Blue Assay with ALS does not recover cell death ","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityCellCultureRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a1f9362-7a3d-405d-a392-1e1c7cbb3fcd","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8cbcb3bd-d524-49c6-b3cb-a71bba8819a8","type":"FunctionalAlteration","dc:description":"Expression of WT and glaucoma variant rescued cell death; ALS mutants did not and they also increased mRNA levels of NF-kB regulated genes","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23721573","rdfs:label":"OPTN knockdown effects neuronal cell death"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0be2ccfe-ff5e-4eac-bf4b-f832d6426f3f","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/506f8ac2-0042-432b-8825-1f388d5e9f9f","type":"FunctionalAlteration","dc:description":"Depletion of OPTN in HeLa cells increased the amount of GFP-SOD1 aggregates.  To test the role of OPTN in the autophagy clearance of protein aggregates – OPTN KD in heLa cells transfected with SOD1 and treated with  (DMSO control) an autophagy activator (rapamycin) and an inhibitor (BafA1)\nActivator significant increase in clearance for control and the inhibitor – 2 fold increase in number of aggregates  in control. The activaor and inhibitor did not have an effect on depleted OPTN.\n\nTo demonstrate a specific role for OPTN in the aggregation phenotype, authors reconstituted depleted OPTN with WT, F178A (a LC3 binding deficent OPTN) and E478G (ubiquitin binding deficient OPTN). WT and and the E478G were able to reduce the amount of SOD1-protein aggregates, the LC3 binding deficient OPTn did not\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23178947","rdfs:label":"OPTN depletion effect on aggragates"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c769c96a-a3be-4545-9f41-982b7bd7cacf","type":"EvidenceLine","dc:description":"This assay shows similar results in autopsy samples in the dysregulation in neuronal cell lines","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/710abe1e-3b5c-4009-956c-aa6dcd170e8f","type":"FunctionalAlteration","dc:description":"1.\tIn transfected NSC-34 cells, WT and E50K optineurin co-localized with vesicular myosin VI, in contrast to E478G or Q398X optineurin mutants, which showed little co-localization with myosin VI. Furthermore, although myosin VI was immunoprecipitated by GFP-Trap in lysates prepared from WT and E50K optineurin expressing cells, little myosin VI was precipitated from E478G or Q398X expressing cells, revealing that the ALS mutants do not bind to myosin VI. This finding was confirmed by immunoprecipitation of cell lysates using an anti-myosin VI antibody: little E478G or Q398X co-precipitated with myosin VI in contrast to WT and E50K optineurin. In TIP-treated cells, significantly fewer optineurin vesicles were formed compared with untreated cells (P < 0.05), and optineurin was localized diffusely throughout these cells, similar to ALS mutant expressing cells\n2.\tSignificantly less VSVG (P < 0.05) reached the cell surface by 120 min in cells expressing E478G or Q398X compared with WT, E50K or EGFP alone. Similarly, when VSVG-positive vesicles were transported from the Golgi apparatus toward the plasma membrane at 60 min after changing to the permissive temperature, significantly fewer cells showed (P < 0.0001) VSVG co-localized with optineurin in E478G or Q398X expressing cells compared with WT and E50K expressing cells\n3.\tALS mutant optineurin is not vesicular and does not co-localize with either LC3 or myosin VI\n4.\tIn optineurin siRNA-treated cells, there is a decreased proportion of mCherry-positive mature autolysosomes without GFP, indicating that fusion between autophagosomes and lysosomes is inhibited. Immunoblotting of cell lysates revealed a significantly increased intensity of LC3-II in cells expressing E478G and Q398X compared with WT and E50K optineurin (P < 0.05), indicating accumulation of autophagosomes, under basal conditions.  Expression of HA-tagged ALS mutant Q398X caused a significant decrease in the proportion of fused autolysosomes per cell, detected by co-expression of tandem mCherry-LC3-GFP construct, under starvation-induced autophagy (P < 0.0001) compared with WT or untransfected cells\n5.\tImmunoblotting for markers of ER stress, namely inositol requiring kinase 1 (IRE1) and spliced X-box binding protein 1 (Xbp1), revealed greater activation of ER stress in cells expressing E478G and Q398X (P < 0.05) compared with WT or E50K. Expression of E478G and Q398X caused a significant increase (P < 0.001) in nuclear immunoreactivity to C/EBP homologous protein (CHOP) compared with WT or E50K optineurin expression. A greater proportion of condensed punctate structures were present in NSC-34 cells expressing E478G and Q398X compared with WT and E50K (P < 0.05) or GFP and untransfected cells (P < 0.0001).\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25859013","rdfs:label":"Dissociation of ALS-linked mutant optineurin from myosin VI "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/2b974b48-bb33-4f51-bacc-ab76a4e6f2c6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f60845cb-8f24-4ebe-911b-54b4d992a247","type":"FunctionalAlteration","dc:description":"While WT was able to recover KD SG clearance, reduce the amount of TIA1 mRNA/protein expression, reduce the amount of TDP-43 localization to SGs and reduce the amount of ubiquitinated TDP-35, most of the ALS mutants were not able to recover these phenotypes.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34258561","rdfs:label":"OPTN Mutants Induce formation of SGs containing High TDP-43"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b628d731-31bb-4c25-ad03-3a188dbff98a","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/603adfcc-dcd4-4ce9-ab60-129c60a1bee4","type":"FunctionalAlteration","dc:description":"Micro-injection of E478G significantly elevated inflammation in the brains with an increase in astrocyte, microglia and neuronal cell death.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30519240","rdfs:label":"E478G microinjection"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/1d8edc80-413c-4c76-bf06-89198175ac65_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d1509f0-2051-43bc-9215-7679752775be","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7825f8be-0e83-4812-89b7-4d4e2584aff9","type":"Finding","dc:description":"TBK1 phosphorylates OPTN at Ser-177. This will then assist in the degradation of protein aggregates in the autophagy-lysosome pathway.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23178947","rdfs:label":"TBK1 phosphorylating OPTN & Effect of Aggregate Degradation ","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/30d7f6c9-ebec-4090-b5de-4cdab1c5b213","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81a0d10c-6698-410e-95c2-4807b7f0e4e4","type":"Finding","dc:description":"Immunohistochemical staining of the spinal cord sections revealed OPTN-immunoreactive skein-like inclusions in some of the spared spinal anterior horn neurons from all 32 SALS cases and all 8 non SOD1 FALS cases. \n\nTo minimize the ppossibility of failing to detect OPTN in SOD1 positive cases due to the absence of inclusion-bearing neurons, 2 color confocal immunofluorescence microscopy using ubiquitin and OPTN antibodies was performed.\nJ-O 2 well characterized ALS transgenic murine models overexpressing ALS SOD1 mutations  -Ubiq+ while OPTN still negative\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21825243","rdfs:label":"Differential involvement of OPTN +/- SOD1 mutants","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fb9908d7-f409-45a2-857b-7d82f54e7e26","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f1081cb-ec0c-4d3a-9e99-44e97d233733","type":"Finding","dc:description":"Spinal cord with the E478 variant revealed loss of myelin from the corticospinal tract and of the anterior horn cells (AHCs). OPTN immunohistochemistry demonstrated increased staining intensity as both OPTN-I and OPTN-C are increased diffusely in the cytoplasm of AHCs of the SALS patients when compared to the controls.  When re-stained with anti-ubiquitin antibodies, skein like inclusions of patients with SALS are reactive with the anti-OPTN-I and C antibodies. OPTN antibodies were also immunoreactive to TDP43-positive cytoplasmic inclusions","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20428114","rdfs:label":"Identification of OPTN Inclusions in Spinal Cord Tissue","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6}],"evidenceStrength":"Definitive","sequence":4939,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/JPYPuPDVpDE","type":"GeneValidityProposition","disease":"obo:MONDO_0013264","gene":"hgnc:17142","modeOfInheritance":"obo:HP_0032113"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1d8edc80-413c-4c76-bf06-89198175ac65-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}